Dear All,

I am working on development of novel pre-clinical models for autism. I have recently submitted a manuscript for my work where I got a reviewer's comment stating "The issue above also raises the importance of testing and characterization of false positive and false negative controls in the model is required to understand the specificity of the model. A more complete exploration of multiple compound, including both positive and negative controls would help to define the value of this screening model."

From the above comment I understand that we need to screen more compounds to prove the specificity of the model. However, I am confused with the negative control drugs. Do negative control drug here means the drug acting on CNS but not in autism or any random drug having no effect on CNS ?

Regards

Shubham Dwivedi

Similar questions and discussions